ObsEva will cut staff by 70% after FDA setback for uterine fibroids candidate linzagolix

After the FDA delivered bad news to ObsEva in July—saying its highly touted uterine fibroids candidate linzagolix wasn’t fit for an on-time approval—the Swiss company said it would undergo a drastic restructuring.